AU6435398A - Prevention and treatment of hepatocellular cancer - Google Patents

Prevention and treatment of hepatocellular cancer

Info

Publication number
AU6435398A
AU6435398A AU64353/98A AU6435398A AU6435398A AU 6435398 A AU6435398 A AU 6435398A AU 64353/98 A AU64353/98 A AU 64353/98A AU 6435398 A AU6435398 A AU 6435398A AU 6435398 A AU6435398 A AU 6435398A
Authority
AU
Australia
Prior art keywords
prevention
treatment
hepatocellular cancer
hepatocellular
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64353/98A
Other languages
English (en)
Inventor
Lisa H. Butterfield
James S. Economou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, Los Angeles
Original Assignee
University of California, Los Angeles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Los Angeles filed Critical University of California, Los Angeles
Publication of AU6435398A publication Critical patent/AU6435398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU64353/98A 1997-02-13 1998-02-13 Prevention and treatment of hepatocellular cancer Abandoned AU6435398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3837597P 1997-02-13 1997-02-13
US60038375 1997-02-13
PCT/US1998/002753 WO1998035981A1 (en) 1997-02-13 1998-02-13 Prevention and treatment of hepatocellular cancer

Publications (1)

Publication Number Publication Date
AU6435398A true AU6435398A (en) 1998-09-08

Family

ID=21899585

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64353/98A Abandoned AU6435398A (en) 1997-02-13 1998-02-13 Prevention and treatment of hepatocellular cancer

Country Status (8)

Country Link
US (1) US20020031520A1 (enExample)
EP (1) EP0979239B1 (enExample)
JP (3) JP3816959B2 (enExample)
KR (1) KR100460583B1 (enExample)
CN (2) CN1739791A (enExample)
AU (1) AU6435398A (enExample)
DE (1) DE69836209D1 (enExample)
WO (1) WO1998035981A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100482920B1 (ko) * 2000-02-10 2005-04-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 간세포암을 치료하기 위한 조성물
FI118263B (fi) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
US8932829B2 (en) 2005-07-07 2015-01-13 Elena Dudich Recombinant alpha-fetoprotein and compositions thereof
GB0617564D0 (en) * 2006-09-06 2006-10-18 Ucl Business Plc Peptides and methods
KR100900742B1 (ko) * 2007-05-17 2009-06-08 크레아젠 주식회사 인간 간암 동물모델 및 이를 이용한 수지상세포-유래 간암면역치료제의 예방 및 치료 효능을 분석하는 방법
WO2011048503A2 (en) * 2009-10-22 2011-04-28 Moro Ricardo J Peptides that bind the alpha-fetoprotein (afp) receptor and uses thereof
SG11201504558TA (en) 2012-12-11 2015-07-30 Einstein Coll Med Methods for high throughput receptor:ligand identification
CN114456272A (zh) 2015-04-03 2022-05-10 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
CN105126074A (zh) * 2015-09-30 2015-12-09 中国药科大学 多肽afp12在制备抗肿瘤药物中的应用
CN105524884A (zh) * 2016-02-29 2016-04-27 时宏珍 Hla-a0201限制性抗afp抗原特异性ctl的制备方法
SG11201808552XA (en) 2016-05-18 2018-10-30 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
IL262606B2 (en) 2016-05-18 2023-04-01 Albert Einstein College Medicine Inc pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
CN113416729B (zh) * 2021-05-18 2022-11-22 遵义医科大学附属医院 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH025866A (ja) * 1988-06-27 1990-01-10 Kansai Shin Gijutsu Kenkyusho:Kk ヒトアルファフェトプロテインドメインｉ遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインｉの製造法及び製造された該ドメインｉ
IT1226551B (it) * 1988-07-29 1991-01-24 Sclavo Spa Peptide sintetico immunologicamente attivo capace di indurre la produzione di anticorpi con elevata specificita' verso l'alfa- fetoproteina e loro impiego in campo diagnostico
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU700975B2 (en) * 1995-01-24 1999-01-14 Merrimack Pharmaceuticals, Inc. Recombinant human alpha-fetoprotein and uses thereof

Also Published As

Publication number Publication date
JP2001515347A (ja) 2001-09-18
EP0979239A4 (en) 2002-09-18
CN1739791A (zh) 2006-03-01
DE69836209D1 (de) 2006-11-30
CN1259139A (zh) 2000-07-05
US20020031520A1 (en) 2002-03-14
WO1998035981A1 (en) 1998-08-20
EP0979239A1 (en) 2000-02-16
KR100460583B1 (ko) 2004-12-08
JP2010222379A (ja) 2010-10-07
EP0979239B1 (en) 2006-10-18
CN1222536C (zh) 2005-10-12
JP3816959B2 (ja) 2006-08-30
JP2006188528A (ja) 2006-07-20
KR20000071226A (ko) 2000-11-25

Similar Documents

Publication Publication Date Title
AU2402395A (en) Cancer treatment and metastasis prevention
ZA979096B (en) Viral and cancer treatment
AU2212299A (en) Compositions and methods for the treatment of tumor
PL335160A1 (en) Treatment of hiv and carcinoma
AU9016898A (en) Methods and compositions for treatment of restenosis
GB9808840D0 (en) Treatment of depression and pharmaceutical preparations therefor
DE69836209D1 (de) Vorbeugung und behandlunhg des hepatozellulären krebses
AU1556497A (en) Agents for the treatment and prevention of aids
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
AU2845400A (en) Treatment and prevention of immune rejection reactions
AU7105498A (en) Combination therapy for the prevention and treatment of osteoporosis
AU4816896A (en) Treatment and prevention of prostatic cancer
AU1293400A (en) Enzymatic treatment and prevention of hypertrophic skin
AU2964199A (en) Prevention and treatment of adhesions
AU5984196A (en) Treatment and prevention of prostatic disease
AU4107797A (en) Compounds for the treatment and prevention of diabetes
HK1025778A (en) Prevention and treatment of hepatocellular cancer
AU3735900A (en) Methods of treatment and prevention of restenosis
AU4799797A (en) Antitumor compositions and methods of treatment
AU1392601A (en) Prevention and treatment of biomaterial-associated infections
AU4556899A (en) Prevention and treatment of sepsis
AUPO955497A0 (en) Treatment of cancer
PL342649A1 (en) Prevention of amyloidogenous diseases and treatment of them
AU2003204325A1 (en) Detection and treatment of cancer
AU2003203632A1 (en) Prevention and treatment of hypergastrinemia